Loading
A phase 2 trial of tarlatamab in lung cancer, run by Asrar Alahmadi, now recruiting.
Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer is a phase 2, interventional study registered as NCT07423585 by Asrar Alahmadi, with a registry enrolment figure of 39 participants, started 2026-03-20 and due to reach its primary completion in 2027-12-31. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Echocardiography Test; Electronic Health Record Review; Magnetic Resonance Imaging; Multigated Acquisition Scan; Questionnaire Administration; Tarlatamab. Conditions listed: Extensive Stage Lung Small Cell Carcinoma. Primary outcome: 6-month progression-free survival (PFS); Rapid progressive disease (PD) on tarlatamab rate probability (Interim analysis for futility monitoring). Lung eligibility wording from the registry: ", metastatic and/or recurrent) SCLC". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Tarlatamab, Amgen, Extensive-stage small-cell lung cancer, Bispecific antibodies and the tag lung-deep-dive.
Shares Tarlatamab, Amgen, Bispecific antibodies, T-cell engagers (bispecific) and the tag lung-deep-dive.
Shares Tarlatamab, Amgen, Bispecific antibodies, T-cell engagers (bispecific) and the tag lung-deep-dive.
Shares Tarlatamab, Amgen, Bispecific antibodies, T-cell engagers (bispecific) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.